Randomized multicenter phase III study of weekly paclitaxel versus three weekly paclitaxel in patients with metastatic breast cancer previously treated with anthracyclines.
Completed
- Conditions
- Metastatic breast cancer patients previously treated with anthracyclines.
- Registration Number
- NL-OMON29217
- Lead Sponsor
- VU medisch centrum
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 160
Inclusion Criteria
1. Histologically or cytologically confirmed metastatic breast cancer;
2. No past or current history of another neoplastic disease, except for curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix uteri, or other cancers cured by surgery alone and with a disease-free interval of longer than 5 years;
Exclusion Criteria
1. Prior treatment with taxanes;
2. Pregnant or breast-feeding females, or females of child-bearing potential not taking adequate methods of birth control;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival.
- Secondary Outcome Measures
Name Time Method 1. Overall survival;<br /><br>2. response rate;<br /><br>3. toxicity;<br /><br>4. quality of life.